# The University of Toronto's Innovation Ecosystem and Some Emerging Therapeutic Technologies

Rohan Alvares, *PhD*Technology Analyst – Life Sciences

August 2023



**O**//Ramp



### Welcome to U of T!

1. Global Excellence

2. An Innovation Powerhouse

3. A Leader in Entrepreneurship







U of T's innovation network owes a lot to the city in which it's located.

One of the world's most livable cities

North America's 4th largest city

Considered the world's most diverse city, with more than 170 languages spoken







#### One World-Class University – Three Distinctive Campuses







- 15,000 faculty (incl Hospital Researchers)
- 10,000 staff (incl Librarians)
- 97,000+ students (incl 27,000+ Int'ntl)
- Partner with >300 companies at any given time (> 600 over past 10 years)

- 19 Faculties and Schools
- 174 Research Centres across all three campuses
- 300 graduate programs, 20,700 Graduate Students
- Created > 600 start-ups, raising > \$2.5B in venture funding over past 10 years



# U of T's position in World University Rankings

	2022	2021	2020	2019	2018
National Taiwan University Ranking	6	3	3	4	4
Times Higher Education World University Rankings	18	18	18	18	21
U.S. News Best Global Universities	18	16	17	18	20
Academic Ranking of World Universities	22	22	23	24	23
QS World University Rankings	34	26	25	29	28

#1

in the world for industry, innovation & infrastructure

TIMES HIGHER EDUCATION IMPACT RANKINGS, 2020

#3

in the world for performance of scientific papers

NATIONAL TAIWAN UNIVERSITY RANKING, 2020

#2 & # 3

in the world for research output – publications & citations

INCITES™, CLARIVATE ANALYTICS (2014-2018), INCLUDING WEB OF SCIENCE CONTENT INDEXED THROUGH 2019-11-29.





#3

in the world for clinical medicine and healthcare

### Clinical Medicine Rankings





2. An Innovation Powerhouse

3. A Leader in Entrepreneurship







#### A Legacy of Discovery and Innovation

At the University of Toronto we celebrate a long history of breakthroughs and discoveries that have saved countless lives and improved societies all over the world.

#### 1921 Insulin

Nobel Prize 1923 – Banting (Best) and Macleod (Collip)

#### 1941

Anti-Blackout Flight Suit

Franks – precursor to modern Space-suit

#### 1961

**Stem Cells** 

Till and McCulloch (Princess Margaret Cancer Centre & U of T)

#### 1988

1<sup>st</sup> Nerve Transplant

Hudson and Mackinnon (St. Michael's Hospital & U of T)

















1930s
Electron Microscope
Burton.

1951 Cardiac Pacemaker


Bigelow and Callaghan (Toronto General Hospital & U of T) 1980s Chemical Laser Nobel Prize 1986 Polanyi 2010s
Deep
Learning
Hinton



### **U** of T has World – Leading Expertise



















# 1,000+ patent applications filed over the last 10 years



2. An Innovation Powerhouse

3. A Leader in Entrepreneurship








IN THE GREATER TORONTO AREA





# A Powerhouse of Innovation & Entrepreneurship

U of T is Canada's leading engine for research-based startups and a global leader in transforming ideas into products and services that impact the world.

600

Startups created in the past decade

\$2.5B

In investment generated

#1

In Canada for research-based startups

Top 5

In university-managed incubators

9,000

Jobs created

U of T named the fastest-rising global institution in PitchBook's 2021 Top 50 rankings of best universities for startup founders.







# NUAK Inhibitors as Therapeutics for Cancer and Fibrosis | P2143

Liliana Attisano

#### Liliana Attisano

Professor University of Toronto

Therapeutic Area:

Oncology

Modality: Small molecule

**Disease Indications:** 

Cancer, Fibrosis

Intellectual Property: AU, CA, CN, EU, JP, US

**Stage of Development:** 


Lead optimization Animal studies



#### **Background**

- Hippo signaling pathway regulates cell proliferation and cell death
- High cell density and stress activate pathway to stop cell proliferation and induce apoptosis
  - Phosphorylation events
- Hippo OFF → pro-oncogenic, pro-fibrotic outcomes
- Promotion of YAP/TAZ phosphorylation → cancer & fibrosis therapeutics

### Hippo pathway linked to cancer and fibrosis



**Fig.** Hippo signalling pathway. Extracellular cues turn on the Hippo pathway which results in phosphorylation and cytoplasmic retention of YAP/TAZ; unphosphorylated TAP/TAZ localise to the nucleus where the exert pro-

oncogenic, pro-fibrotic functions.



# NUAK Inhibitors as Therapeutics for Cancer and Fibrosis | P2143

Liliana Attisano

#### **Technology**

- NUAK2 / NUAK1 promotes YAP and TAZ oncogenic and fibrotic activity
- Small molecule NUAK inhibitors prevents tumorigenic and fibrotic properties in cells and in mice models
  - OICR Drug Discovery Program

#### **Benefits**


- Two classes of novel inhibitor compounds for NUAKs: IC50 in the nM range
- NUAK1 and NUAK2 are elevated in broad disease indications based on Cancer and Fibrosis
- Drug screening capabilities: new opportunity to develop kinase inhibitors

#### **Applications**


- Cancer therapeutic Multiple solid cancers: breast, colon, bladder, HNSCC, others
- Fibrosis therapeutic Kidney, lung, liver, pancreas, others

#### **Project Status**

Mice studies conducted



**Fig.** Negative regulation of the Hippo pathway by NUAK2 promotes oncogenesis and fibrosis.



**Fig.** A small molecule compound (NUAK inhibitor) inhibits tumor growth in a late-stage breast cancer model (orthotopic MDA-MB-231) in immunocompromised (NSG) mice leading to increased survival.



#### Peptide Therapeutic for Parkinson's Disease | P2251

Philip M. Kim, Suneil Kalia, Lorraine Kalia

\*Philip M. Kim, YSuneil Kalia, YLorraine Kalia Professors \*University of Toronto YUniversity Hospital Network

Therapeutic Area: Neurology

Modality: Gene Therapy

**Disease Indications:** Parkinson's

Intellectual Property: PCT (2022)

**Stage of Development:** Animal studies





#### **Background**

- Parkinson's Disease
  - Results from degeneration of dopamine-producing neurons
- No disease-modifying therapies available

#### **Technology**

- Screening Platform to identify peptidebased protein-protein interaction inhibitors
- Applied to alpha-synuclein based models of Parkinson's disease
- Optimized a top peptide candidate (PDpep1.3)







#### Peptide Therapeutic for Parkinson's Disease | P2251

Philip M. Kim, Suneil Kalia, Lorraine Kalia


#### **Benefits**

- Novel screening platform enabled discovery of proteinprotein interaction hits
- Lead compound with nanomolar target engagement
- Fully novel target in an under-explored molecular pathway
- Proven in vivo efficacy


#### **Project Status**


 Rat, earthworm and human cell line studies conducted

**Fig.** In a commonly used rat preclinical model of Parkinson's disease, viral mediated expression of A53T alpha-synuclein causes degeneration of TH+ dopamine neurons in the substantia nigra compared to empty viral vector (EV). PDpep1.3 reduces degeneration of dopamine neurons in this model (left panel) and rescues dopamine levels in the striatum, which receives projections from the affected substantia nigra (right panel).



**Fig.** PDpep1.3 reduces alpha-synuclein protein levels in rat cortical neurons expressing the disease-causing A53T alpha-synuclein mutant (left panel) and normalizes A53T alpha-synuclein levels to those of isogenic controls in dopamine neurons derived from human iPSCs (right panel).





### Why Partner With U of T?

#### **Culture of Excellence:**

- History of Innovation and Discovery
- Large Well-equipped Researcher Base
- Global Respect (Independent Rankings)
- Global Reach (Partnerships)

#### **Responsive to Industry Requirements:**

- Industry Interface from SMEs to Multi-Nationals
- Expertise with Government Funding Support
- Flexible IP terms
- Exposure via Research and Internships to train tomorrow's thought leaders

U of T is Canada's innovation powerhouse where Canadian and international innovators and entrepreneurs can launch game-changing ventures that drive economic growth, social change, and entirely new industries.



#### Connect with us



#### **Research and Innovation (IPO)**

Email industry.connects@utoronto.ca

rohan.alvares@utoronto.ca

Visit <u>research.utoronto.ca/connect-with-us</u> to learn more.

#### **Entrepreneurship (UTE)**

- Subscribe to the U of T Entrepreneurship weekly newsletter
- Follow @UofTStartup on social media
- Email entrepreneurs@utoronto.ca
- **Sign-up** for the *Deep Tech Download* quarterly digest
- Go to bluedoor.utoronto.ca to learn about partnerships



Visit entrepreneurs.utoronto.ca to learn more.